SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 7/25/2017 10:48:18 AM - Followers: 719 - Board type: Free - Posts Today: 28

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 07/13/2017 04:04:10 PM
IPIX News: Current Report Filing (8-k) 06/07/2017 04:19:05 PM
IPIX News: Quarterly Report (10-q) 05/09/2017 04:09:09 PM
IPIX News: Amended Statement of Ownership (sc 13g/a) 04/28/2017 12:50:45 PM
IPIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
PostSubject
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#191274  Sticky Note >80% of Prurisol patients should finish six weeks sox040713 07/21/17 11:47:02 AM
#190524  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets, Blogs sox040713 07/16/17 03:13:55 PM
#190087  Sticky Note From the June conference call, sox040713 07/13/17 06:15:25 PM
#187089  Sticky Note Prurisol's Importance: data We are nearing the very DaubersUP 06/23/17 04:59:13 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#191571   Your focus on hourly share price is tedious schooneratsea 07/25/17 10:48:18 AM
#191570   I'd hate to see where the stock price Rdunn88 07/25/17 10:34:59 AM
#191568   $IPIX - Innovation Pharmaceuticals Phase 2 PoC Trial TheHound 07/25/17 10:29:29 AM
#191566   $IPIX Ongoing Kevetrin Ph 2 ---> A Phase TheHound 07/25/17 10:25:38 AM
#191565   $IPIX ---> new website means u have to TheHound 07/25/17 10:23:45 AM
#191564   $IPIX - A MUST READ ----> https://seekingalpha.com/article/4088788-innovation-ph TheHound 07/25/17 10:22:13 AM
#191563   Very interesting!! Thanks cabel 07/25/17 10:09:33 AM
#191560   FROM Lilly Report Today: seek the light 07/25/17 09:19:35 AM
#191557   The last Aspire dollar, Leo will announce 3 Rdunn88 07/25/17 09:14:03 AM
#191556   Leo better hurry up and find that "properly" Rdunn88 07/25/17 09:10:15 AM
#191553   believe it when we see it. MXAMDUD 07/25/17 09:04:56 AM
#191552   Is it possible that less than stellar results oddone33320 07/25/17 08:49:38 AM
#191551   my guess would be that IP talking to To infinity and beyond! 07/25/17 08:43:24 AM
#191549   Forget the Phase 3's,... cabel 07/25/17 08:25:51 AM
#191548   Is that what the sales dept. told you? alwaysdreaming 07/25/17 08:24:38 AM
#191547   1 and 2 are 2019 milestones -- especially scottsmith 07/25/17 08:12:33 AM
#191546   Assuming we partner and have enough funds to Scottwny 07/25/17 08:10:41 AM
#191545   Would it be nice if we got more JUST 10-11-12 07/25/17 07:52:58 AM
#191544   no news. MXAMDUD 07/25/17 06:35:58 AM
#191543   GREAT ARTICLE ABOUT INNOVATION PHARMACEUTICALS georgejjl 07/24/17 11:51:09 PM
#191542   Prurisol alone is worth at least $10 Billion!!! georgejjl 07/24/17 11:41:22 PM
#191541   Prurisol Know the competition. Realistically Otezla is no competition georgejjl 07/24/17 11:29:44 PM
#191540   Treatment Ends in Trial Showing That Brilacidin Is georgejjl 07/24/17 10:44:31 PM
#191539   Thanks Sox. I knew those short volume rebelwithacause 07/24/17 09:08:05 PM
#191538   Luckily for me when IPIX went down 3.56% georgejjl 07/24/17 09:02:52 PM
#191536   Alan, your daily FINRA short sales numbers are taas 07/24/17 08:19:42 PM
#191535   No new news here, and it's a few nerby 07/24/17 07:51:53 PM
#191534   LilyGDog, you are welcome and good luck! sox040713 07/24/17 07:23:13 PM
#191533   Someone called FINRA to ask what the short sox040713 07/24/17 07:00:16 PM
#191532   Here's a link to the short volume file. sox040713 07/24/17 06:50:34 PM
#191530   Here it is in context. F1ash 07/24/17 06:37:45 PM
#191529   FINRA short sales of IPIX AlanC 07/24/17 06:25:12 PM
#191528   A properly structured license deal would provide IPIX frrol 07/24/17 04:49:34 PM
#191526   I am as optimistic as anyone for a biopa 07/24/17 03:01:35 PM
#191525   Lol, no worries, we will still extend an mdphd2008 07/24/17 02:34:30 PM
#191523   What a bummer..Im like 5 shares short of BIzzy 07/24/17 02:28:28 PM
#191520   Not necessarily, some people were fortunate to be mdphd2008 07/24/17 02:21:03 PM
#191519   That's what I am counting on; oh plus LilyGDog 07/24/17 02:21:02 PM
#191518   Someone who holds 250k shares of IPIX is tykundegex 07/24/17 02:18:09 PM
#191517   If someone can accumulate 250k, I can easily mdphd2008 07/24/17 02:14:15 PM
#191516   It is the quiet before the buying frenzy! LilyGDog 07/24/17 02:13:15 PM
#191514   I'm not holding 250k, Dud has $2500 moves DrBones 07/24/17 01:57:37 PM
#191513   Is 250k the magic number to be in mdphd2008 07/24/17 01:54:36 PM
#191512   $IPIX - A MUST READ ----> https://seekingalpha.com/article/4088788-innovation-pharmaceuticals-sto TheHound 07/24/17 01:48:30 PM
#191511   quiet sideways price action Until right now....watch out 123tom 07/24/17 01:43:26 PM
#191510   im hearing just the opposite from most tb TheHound 07/24/17 01:42:57 PM
#191508   Or, they're like me and getting ready to KarinCA 07/24/17 01:41:06 PM
#191506   I'd like a higher base to start the joseytheoutlawwales 07/24/17 01:38:34 PM
#191505   we shall see. TheHound 07/24/17 01:37:32 PM
#191504   Seems like the market is completely ignoring that fact. joseytheoutlawwales 07/24/17 01:33:01 PM
PostSubject